LGND FY 2020 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$164M+36.0% YoY

Gross Profit

$133M81.4% margin

Operating Income

$38M22.9% margin

Net Income

-$3M-1.8% margin

EPS (Diluted)

$-0.18

Cash Flow

Operating Cash Flow

$55M

Free Cash Flow

$50M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$653M

Stockholders' Equity

$710M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$120M	+36.0%
Gross Profit	$133M	$109M	+22.2%
Operating Income	$38M	$807M	-95.4%
Net Income	-$3M	$629M	-100.5%